Skip to content

Ver Research Paper

This list includes original research and reviews of literature about psychedelic compounds (such as LSD, psilocybin, and MDMA), with a strong focus on research in humans.

The list is not intended to be comprehensive. This collection exists to present a broad survey of the currently available literature, and to introduce readers to the clinical psychedelic research literature. Readers may wish to investigate the reference lists of any paper that interests them to locate further reports.

View our official Publication Policy for papers and presentations mentioning MAPS-sponsored research.

Featured MDMA Research

  • Feduccia, A. A., Holland, J., & Mithoefer, M. C. (2017) Progress and promise for the MDMA drug development program. Psychopharmacology 1-11.
  • Mithoefer M, Grob C, Brewerton T (2016) Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. The Lancet Psychiatry 3 (5): 481–488
  • Heifets B, Malenk R (2016) MDMA as a Probe and Treatment for Social Behaviors. Cell 166: 269-272
  • Danforth A, Struble C, Yazar-Klosinski B, Grob C (2016) MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults. Progress in Neuro-Psychopharmacology & Biological Psychiatry 64: 237–249
  • Mithoefer M, Wagner M, Mithoefer A, Jerome L, Martin S, Yazar-Klosinski B, Michel Y, Brewerton T, Doblin R (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol 27(1): 28-39
  • Oehen P, Traber R, Widmer V, Schnyder U (2013) A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)- assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). Journal of Psychopharmacology 27(1): 40–52
  • Jerome L, Schuster S, Yazar-Klosinski B (2013) Can MDMA Play a Role in the Treatment of Substance Abuse? Current Drug Abuse Reviews 6: 54-62
  • Mithoefer M, Wagner M, Mithoefer A, Jerome L, Doblin R (2010) The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology 25(4): 439–452
  • Sumnall H, Cole J, Jerome L (2006) The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy. Journal of Psychopharmacology 20(5): 670–682
  • Greer G, Tolbert R (1986) Subjective Reports of the Effects of MDMA in a Clinical Setting. Journal of Psychoactive Drugs 18(4): 319-327

Additional MDMA Resources


Featured Ibogaine Research


Featured LSD Research


Additional Psychedelic Research

  • Barbanoj MJ, Riba J, Clos S, Gimenez S, Grasa E, Romero S (2008) Daytime ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers. Psychopharmacology (Berl) 196: 315-326 (PDF)
  • Bedi G, Phan KL, Angstadt M, de Wit H (2009) Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology (Berl) 207: 73-83 (PDF)
  • Bouso JC, Doblin R, Farre M, Alcazar MA, Gomez-Jarabo G (2008) MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J Psychoactive Drugs 40: 225-236 (PDF)
  • Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX (2007) Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology (Berl) 195: 415-24 (PDF)
  • Doblin R (1998) Dr. Leary's Concord Prison Experiment: a 34-year follow-up study. J Psychoactive Drugs 30: 419-426. (PDF) ( HTML version). Additional commentary is available in Ralph Metzner's Reflections on the Concord Prison Experiment and the Follow-Up Study.
  • Dumont GJ, Sweep FC, van der Steen R, Hermsen R, Donders AR, Touw DJ, van Gerven JM, Buitelaar JK, Verkes RJ (2009)Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci 4: 359-366 (PDF)
  • Dyck E (2005) Flashback: psychiatric experimentation with LSD in historical perspective. Can J Psychiatry 50: 381-388 (PDF)
  • Fantegrossi WE, Murnane KS, Reissig CJ (2008) The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75: 17-33 (PDF)
  • Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX (2000) 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacology 23: 388-95 (PDF)
  • Geyer MA, Vollenweider FX (2008) Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci 29: 445-453. (PDF)
  • Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar KA, Hermle L, Bull U, Sass H (1999) Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 20: 565-581 (PDF)
  • Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Lindenblatt H, Hermle L, Spitzer M, Sass H (1999)Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl) 142: 41-50 (PDF)
  • Griffiths R, Richards W, Johnson M, McCann U, Jesse R (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacology 22: 621-632 (PDF)
  • Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187: 268-83; discussion 284-292 (PDF)
  • Halpern JH, Pope HG, Jr. (1999) Do hallucinogens cause residual neuropsychological toxicity? Drug Alcohol Depend 53: 247-256 (PDF)
  • Halpern JH, Sherwood AR, Passie T, Blackwell KC, Ruttenber AJ (2008) Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Med Sci Monit 14: SR15-22 (PDF)
  • Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl) 172: 145-56 (PDF)
  • Johnson M, Richards W, Griffiths R (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacology 22: 603-620 (PDF)
  • Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY (2007) Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs 39: 13-9 (PDF)
  • Kurland AA, Grof, S., Pahnke, W. N., Goodman, L.E. (1973) Psychedelic Drug Assisted Psychotherapy. In Patients With Terminal Cancer. In: Goldberger IK, Malitz S, Kutscher AH (eds) Psychotheramacological Agents for the Terminally Ill and Bereaved 1973,. Columbia University Press, New York, NY, pp 86-133 (PDF)
  • Liechti ME, Gamma A, Vollenweider FX (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 154: 161-168 (PDF)
  • Ludwig A, Levine J, Stark L, Lazar R (1969) A clinical study of LSD treatment in alcoholism. Am J Psychiatry 126: 59-69 (PDF)
  • Mangini M (1998) Treatment of alcoholism using psychedelic drugs: a review of the program of research. J Psychoactive Drugs 30: 381-418 (PDF)
  • Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006) Safety, tolerability and efficacy of psilocybin in 9 patients with Obsessive-Compulsive Disorder. J Clin Psychiatry 67: 1735-11740 (PDF)
  • Nichols DE (2004) Hallucinogens. Pharmacol Ther 101: 131-181 (PDF)
  • Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008) The pharmacology of lysergic Acid diethylamide: a review. CNS Neurosci Ther 14: 295-314 (PDF)
  • Passie T, Seifert J, Schneider U, Emrich HM (2002) The pharmacology of psilocybin. Addict Biol 7: 357-64 (PDF)
  • Riba J, Rodriguez-Fornells A, Barbanoj MJ (2002) Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively. Psychopharmacology (Berl) 165: 18-28 (PDF)
  • Sewell RA, Halpern JH, Pope HG, Jr. (2006) Response of cluster headache to psilocybin and LSD. Neurology 66: 1920-1922 (PDF)
  • Strassman RJ (1995) Hallucinogenic drugs in psychiatric research and treatment. Perspectives and prospects. The Journal of Nervous and Mental Disease 183: 127-138 (PDF)
  • Strassman RJ, Qualls C, Berg L (1996) Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Biological Psychiatry 39: 784-795 (PDF)
  • Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16: 357-372 (PDF)
  • Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB (2007) The Effects of the Preferential 5-HT2A Agonist Psilocybin on Prepulse Inhibition of Startle in Healthy Human Volunteers Depend on Interstimulus Interval. Neuropsychopharmacology 32(9):1876-1887 (PDF)

The Psychedelic Bibliography includes a larger list of published research.

General principles

RePEc (Research Papers in Economics) is a collaborative effort of hundreds of volunteers in 95 countries to enhance the dissemination of research in Economics and related sciences. The heart of the project is a decentralized bibliographic database of working papers, journal articles, books, books chapters and software components, all maintained by volunteers. The collected data are then used in various services that serve the collected metadata to users or enhance it.

So far, over 1,900 archives from 95 countries have contributed about 2.3 million research pieces from 2,800 journals and 4,500 working paper series. About 50,000 authors have registered and 75,000 email subscriptions are served every week. See below on how you can be part of this initiative.

RePEc services

The following are services that use (principle) and contribute RePEc data. They also report usage statistics that can be used towards the RePEc rankings.

Additional websites using RePEc

The RePEc bibliographic data is in the public domain and thus used by other services as well. The following are the ones we know of, and unfortunately none report usage statistics back to LogEc.

Adding bibliographic information to RePEc

The basic principle is that publishers index their content themselves into RePEc. They host the metadata on their http or ftp site, following the Guildford Protocol, which indicates how the metadata archive should be structured. Then, the syntax of the metadata template syntax is guided by ReDIF, the Research Documents Information Format.

If you intend to contribute information about your publications to RePEc, you may read the above documents or use these step-by-step instructions or sample templates. The same instructions apply for commercial publishers or research institutes.

RePEc archive maintainers may also make good use of the template syntax and link checker, of tips and tricks and the FAQ.

Mailing lists for RePEc:

  • RePEc-announce: general information about RePEc developments
  • RePEc-run: discussion of technical matters regarding RePEc services

Volunteers

RePEc is entirely based on the contributions of volunteers: Maintainers of RePEc archives, editors at NEP and MPRA, and those who run the various RePEc services. If you want to get involved check out our volunteer opportunities or contact any member of the RePEc team.

RePEc emerged from the NetEc group, created in 1992, which received support for its WoPEc project between 1996-1999 by the Joint Information Systems Committee (JISC) of the UK Higher Education Funding Councils, as part of its Electronic Libraries Programme (eLib). RePEc was created in June 1997 to decentralize the work done by WoPEc and thus make it independent of grant needs. RePEc is then guaranteed to remain free for all parties.

Contacts

Each RePEc service has contact details; for any question, please email them. For general enquiries about RePEc, in particular to open a RePEc archive, contact Kit Baum or Christian Zimmermann.